Discovery Partners International, Inc. (DPI), and Infinity Pharmaceuticals, Inc., a private company, have entered into a definitive merger agreement to create a new public entity focused on cancer drug discovery and development. The combined company, to be known as Infinity Pharmaceuticals, Inc., will operate from IPI’s current headquarters in Cambridge, MA, be publicly traded, and will have a lead product candidate in multiple Phase I clinical trials, a second product candidate scheduled ...